Salvia Miltiorrhiza

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: heart inflammation pain

Research Overview

Research on Salvia miltiorrhiza (Danshen) is extensive but dispersed across pharmacognosy, pharmacology, and translational studies. The most studied areas are cardiovascular and cerebrovascular indications, reflecting long-standing traditional use and a large experimental literature emphasizing antioxidative, anti-inflammatory, antifibrotic, and vasculoprotective actions. Chemical and mechanistic work has focused on two major constituent classes: lipophilic diterpenoid quinones (notably tanshinones such as tanshinone IIA) and hydrophilic phenolic acids (notably salvianolic acids such as salvianolic acid B). In parallel, there is a substantial body of research on production and standardization—especially biotechnological approaches (e.g., in vitro culture, elicitation, hairy roots, endophytic fungi, and bioreactors) to increase yields of phenolic acids to meet demand.

The strongest evidence from the abstracts supports that Danshen contains multiple bioactive compounds with reproducible antioxidant and anti-inflammatory activities and plausible multi-target mechanisms relevant to vascular disease and tissue injury. Mechanistic studies repeatedly implicate pathways linked to oxidative stress, inflammatory signaling, and vascular remodeling; network pharmacology analyses in diabetic nephropathy further converge on targets such as AKT1, VEGFA, IL6, TNF, MAPKs, and STAT3, with docking suggesting strong binding of salvianolic acid B to several DN-relevant targets. Evidence is also accumulating for anticancer-related activities at the preclinical level, including inhibition of proliferation, metastasis, angiogenesis, and modulation of apoptosis/autophagy and the tumor microenvironment; specific mechanistic findings include tanshinone I–mediated suppression of glycolysis and downstream epigenetic effects (reduced H3K18 lactylation) in ovarian cancer models. Additionally, there is growing interest in Danshen constituents as chemo-adjuvants to enhance efficacy and mitigate chemotherapy-associated toxicities, and in formulation science (e.g., nano-delivery) to improve delivery of poorly soluble compounds such as tanshinone IIA.

Key gaps remain in clinical validation and in translating mechanistic findings into standardized, evidence-based interventions. Multiple reviews emphasize the need for more rigorous human studies to confirm efficacy and safety in oncology (including chemo-adjuvant use) and in non-cardiovascular indications such as diabetic nephropathy, as much of the current support is preclinical, computational, or based on heterogeneous experimental designs. Additional needs include clearer characterization of adverse effects and drug–drug interactions, improved standardization of extracts/constituent dosing, and stronger pharmacokinetic/pharmacodynamic data—particularly for lipophilic tanshinones and advanced formulations. Emerging mechanistic areas (e.g., ferroptosis modulation in myocardial injury) appear promising but are still under-defined and require targeted in vivo studies and eventual clinical testing.

1. What conditions has Salvia miltiorrhiza been studied for?

  • Cardiovascular diseases: widely used and studied for coronary heart disease and related cardiovascular conditions; also studied in the setting of myocardial infarction (MI) and post-MI myocardial injury (including cardiomyocyte ferroptosis).

  • Cerebrovascular diseases: repeatedly cited as a major traditional and research focus.

  • Diabetic nephropathy (DN): studied in clinical trials/systematic reviews (as summarized in a DN-focused review) and in mechanistic/network pharmacology work identifying targets and pathways relevant to DN.

  • Cancer: studied broadly for anticancer effects and as a chemo-adjuvant (to enhance chemotherapy efficacy and/or reduce side effects); specific preclinical evidence is described for ovarian cancer (tanshinone I).

  • Metabolic syndrome-related conditions: discussed in a review context for diabetes mellitus, obesity, atherosclerosis, and high blood pressure, including Salvia miltiorrhiza alone and in combinations (e.g., with Carthamus tinctorius; Danhong injection).

  • Other areas mentioned in broader reviews: antioxidative, neuroprotective, antifibrotic, anti-inflammatory, and antineoplastic activities (these are activity areas rather than single diagnoses, but they map to multiple disease contexts).

2. Does it work in treating those conditions? Summarize the evidence.

  • Cardiovascular disease / MI (preclinical evidence): In a mouse MI model and an in vitro cardiomyocyte ferroptosis model, Salvia miltiorrhiza (Danshen/DS) suppressed cardiomyocyte ferroptosis and improved myocardial damage indicators, with effects linked to Nrf2 signaling (increased Nrf2, xCT, GPX4; reduced ferrous iron and MDA; increased GSH and SOD). The protective effect was partly inhibited in Nrf2 knockout/knockdown contexts, supporting a mechanism-based effect in these models.

  • Diabetic nephropathy (mixed clinical + mechanistic evidence): A DN-focused review states that several clinical trials and systematic reviews indicate “definite benefits” on kidneys of diabetic patients, and that laboratory studies support multi-pathway actions (metabolism, renal hemodynamics, oxidative stress, inflammation, fibrosis, autophagy). A separate network pharmacology/docking study identified overlapping SM–DN targets (e.g., AKT1, VEGFA, IL6, TNF, MAPKs, STAT3) and reported that salvianolic acid B docked more stably than tanshinone IIA to certain DN-related targets (e.g., TNF, NOS2, AKT1). Limitations: the abstracts do not provide trial sizes, endpoints, or effect sizes; network pharmacology/docking is hypothesis-generating rather than definitive clinical proof.

  • Cancer (mostly preclinical and review-level evidence; limited clinical confirmation): A chemo-adjuvant review (2002–2022 literature) concludes that multiple constituents (salvianolic acids, rosmarinic acid, tanshinones, cryptotanshinone, etc.) enhanced chemotherapy efficiency and/or reduced side effects in reported studies, via mechanisms such as inhibiting proliferation/metastasis/angiogenesis and inducing apoptosis/autophagy while modulating tumor microenvironment and immunity; it explicitly notes that further clinical studies are required. A separate study described tanshinone I inhibiting ovarian cancer cell proliferation in vitro and in vivo, linked to downregulation of glycolysis genes (HK2, PFK, ENO2, LDHA), reduced lactate and H3K18 lactylation, and changes in tumor-associated gene expression and immunosuppressive microenvironment—strong mechanistic preclinical support, but not clinical efficacy evidence.

  • Cerebrovascular disease and other traditional indications: Broad reviews state extensive historical use and many pharmacological studies focusing on cardiovascular/cerebrovascular effects, but the provided abstracts do not detail specific controlled clinical outcomes for cerebrovascular endpoints.

  • Metabolic syndrome (review-level, not definitive): A review suggests Salvia miltiorrhiza (alone and in combinations such as Danhong injection) has mechanistic potential relevant to diabetes/metabolic disease (anti-inflammatory, anti-glycemic, anti-thrombotic), but the abstract excerpt does not provide direct clinical efficacy results.

3. What health benefits does it have?

  • Cardioprotective/vascular-related benefits (preclinical + traditional use): Longstanding use and extensive study for coronary heart disease and cerebrovascular diseases; in MI models, DS reduced markers consistent with myocardial injury and ferroptosis and improved antioxidant defenses via Nrf2-associated pathways.

  • Antioxidant and anti-lipid peroxidation effects: Reviews and the MI/ferroptosis study support antioxidative stress effects (e.g., reduced ROS/MDA; increased GSH and SOD activity) and inhibition of lipid peroxidation processes relevant to ferroptosis.

  • Anti-inflammatory effects: Mentioned across reviews; DN network pharmacology highlights inflammatory mediators/targets (e.g., TNF, IL6) among key nodes, consistent with anti-inflammatory potential.

  • Renal protective potential in diabetes (DN): Clinical trials/systematic reviews (as summarized) suggest kidney benefits in diabetic patients; mechanistic studies implicate effects on oxidative stress, inflammation, fibrosis, autophagy, and renal cell protection (endothelial cells, podocytes, epithelial cells, mesangial cells).

  • Anticancer and chemo-adjuvant potential: Constituents are reported to inhibit proliferation/metastasis/angiogenesis and induce apoptosis/autophagy; may improve chemotherapy side effects in reported studies (with the important caveat that stronger clinical validation is still needed).

  • Bioactive constituent classes with plausible activity: Hydrophilic phenolic acids (e.g., salvianolic acid B) and lipophilic diterpenoid quinones (e.g., tanshinone IIA) are repeatedly highlighted as major active groups with broad bioactivities (antioxidant, anti-inflammatory, and others).

4. Does it have any downsides or side effects?

The provided abstracts give limited direct detail on adverse effects, but they do indicate that safety and interactions are relevant considerations.

  • Side effects and drug interactions are recognized concerns: One broad review explicitly states it summarizes “side effects, and drug interactions” of Salvia miltiorrhiza, implying that clinically relevant adverse effects and interaction risks exist, though the abstract does not list them.

  • Potential for interactions in oncology settings: The chemo-adjuvant review focuses on combining Salvia miltiorrhiza constituents with chemotherapy to enhance efficacy and reduce side effects; this combination-oriented use inherently raises the possibility of herb–drug interactions (beneficial or harmful), but the abstract does not specify interaction types, contraindications, or safety outcomes.

  • Evidence limitations: Several claims are based on preclinical models, reviews, and network pharmacology/docking; these do not substitute for comprehensive human safety data (dose-related toxicity, long-term use, special populations).

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The abstracts do not provide classic pharmacogenomic findings (e.g., specific human gene variants predicting response or toxicity), but they do include mechanistic genetics that may be relevant.

  • Nrf2 pathway dependence (genetic knockout evidence): In the MI/ferroptosis study, the protective effect of DS was partly inhibited in Nrf2 knockout/knockdown models. This suggests that individuals with reduced Nrf2 pathway function (due to genetic variation or other factors) might theoretically experience reduced benefit for ferroptosis-related cardioprotection. However, this is an inference from animal/cell models, not a demonstrated human pharmacogenomic association.

  • Multi-target network mechanisms include genes/proteins often variable in humans: The DN network pharmacology analysis highlights targets such as AKT1, TNF, IL6, VEGFA, STAT3, EGFR, TP53. While these are biologically important and can vary across individuals and diseases, the abstract does not link specific polymorphisms to clinical response or adverse events with Salvia miltiorrhiza.

  • Bottom line: Based on these abstracts alone, there is insufficient evidence to claim Salvia miltiorrhiza is beneficial or harmful for specific human genetic variants in a clinically actionable way; the strongest genetics-related signal presented is mechanistic dependence on Nrf2 signaling in preclinical MI models.

References

  1. Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology.
    Chun-Yan Su, Qian-Liang Ming, Khalid Rahman, Ting Han, Lu-Ping Qin (2015) - Chinese journal of natural medicines
  2. Salvia miltiorrhiza in Treating Cardiovascular Diseases: A Review on Its Pharmacological and Clinical Applications.
    Jie Ren, Li Fu, Shivraj Hariram Nile, Jun Zhang, Guoyin Kai (2019) - Frontiers in pharmacology
  3. Bioactivities, biosynthesis and biotechnological production of phenolic acids in Salvia miltiorrhiza.
    Min Shi, Fenfen Huang, Changping Deng, Yao Wang, Guoyin Kai (2019) - Critical reviews in food science and nutrition
  4. Prospective therapeutic potential of Tanshinone IIA: An updated overview.
    Mohammad Azam Ansari, Farheen Badrealam Khan, Haaris Ahsan Safdari, Ahmad Almatroudi, Mohammad A Alzohairy, Mohammadreza Safdari, Mehran Amirizadeh, Suriya Rehman, Mohammad Javed Equbal, Mehboob Hoque (2021) - Pharmacological research
  5. Adjuvant role of Salvia miltiorrhiza bunge in cancer chemotherapy: A review of its bioactive components, health-promotion effect and mechanisms.
    Jiayan Huang, Jiaojiao Zhang, Chengtao Sun, Ruiwen Yang, Miaomiao Sheng, Jiangning Hu, Guoyin Kai, Bing Han (2024) - Journal of ethnopharmacology
  6. Exploring the mechanisms underlying the therapeutic effect of Salvia miltiorrhiza in diabetic nephropathy using network pharmacology and molecular docking.
    Lili Zhang, Lin Han, Xinmiao Wang, Yu Wei, Jinghui Zheng, Linhua Zhao, Xiaolin Tong (2021) - Bioscience reports
  7. Tanshinone I reprograms glycolysis metabolism to regulate histone H3 lysine 18 lactylation (H3K18la) and inhibits cancer cell growth in ovarian cancer.
    Zhou Jin, Lin Yun, Peng Cheng (2025) - International journal of biological macromolecules
  8. Salvia miltiorrhiza suppresses cardiomyocyte ferroptosis after myocardial infarction by activating Nrf2 signaling.
    Yu-Ting Wu, Guo-Yong Zhang, Lei Li, Bin Liu, Ru-Yu Wang, Rong-Qiang Song, Yue Hua, Yi-Ming Bi, Xin Han, Feng Zhang, Dong Wang, Ling-Peng Xie, Ying-Chun Zhou (2024) - Journal of ethnopharmacology
  9. Effect and pharmacological mechanism of Salvia miltiorrhiza and its characteristic extracts on diabetic nephropathy.
    Luqi Cai, Yu Chen, Huizhong Xue, Yimeng Yang, Yuqi Wang, Junhe Xu, Chunyan Zhu, Long He, Yonghua Xiao (2024) - Journal of ethnopharmacology
  10. Pharmacological potential of the combination of Salvia miltiorrhiza (Danshen) and Carthamus tinctorius (Honghua) for diabetes mellitus and its cardiovascular complications.
    John O Orgah, Shuang He, Yule Wang, Miaomiao Jiang, Yuefei Wang, Emmanuel A Orgah, Yajun Duan, Buchang Zhao, Boli Zhang, Jihong Han, Yan Zhu (2020) - Pharmacological research
  11. Overview ofSalvia miltiorrhizaas a Potential Therapeutic Agent for Various Diseases: An Update on Efficacy and Mechanisms of Action
    Inyong Jung, Hyerin Kim, Seongcheol Moon, Hyuk Lee, Bonglee Kim (2020)
  12. Diterpenoid tanshinones inhibit gastric cancer angiogenesis through the PI3K/Akt/mTOR signaling pathway.
    Jie-Ru Yu, Yu-Yue Liu, Yang-Yang Gao, Li-Hui Qian, Jia-Lin Qiu, Pei-Pei Wang, Guang-Ji Zhang (2024) - Journal of ethnopharmacology
  13. Tanshinone-IIA mediated neuroprotection by modulating neuronal pathways.
    Kajal Sherawat, Sidharth Mehan (2023) - Naunyn-Schmiedeberg's archives of pharmacology
  14. Therapeutic potentials and mechanisms of the Chinese traditional medicine Danshensu.
    Jinli Zhang, Qianqian Zhang, Guang Liu, Ning Zhang (2019) - European journal of pharmacology
  15. The Effect of Salvianolic Acid on Vascular Protection and Possible Mechanisms.
    Yalan Wu, Suowen Xu, Xiao Yu Tian (2020) - Oxidative medicine and cellular longevity
  16. Salvia miltiorrhiza: A source for anti-Alzheimer's disease drugs.
    Xiu-Zhen Zhang, Shao-Song Qian, Yue-Jie Zhang, Rui-Qi Wang (2016) - Pharmaceutical biology
  17. Recent developments in
    Lei Luo, Juan Xue, Zheng Shao, Zhang Zhou, Wenqian Tang, Jinxin Liu, Hongfei Hu, Fan Yang (2023) - Frontiers in pharmacology
  18. Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer.
    Zhou Jin, Yu Chenghao, Peng Cheng (2021) - Frontiers in pharmacology
  19. Tanshinone Content Prediction and Geographical Origin Classification of
    Yaoyao Dai, Binbin Yan, Feng Xiong, Ruibin Bai, Siman Wang, Lanping Guo, Jian Yang (2024) - Foods (Basel, Switzerland)
  20. Pharmacological actions and therapeutic applications of Salvia miltiorrhiza depside salt and its active components.
    Wen-yu Wu, Yi-ping Wang (2012) - Acta pharmacologica Sinica


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!